All Pharma News
Idera Announces Name Change to Aceragen & Provides Near-Term Strategic Outlook

Idera Announces Name Change to Aceragen & Provides Near-Term Strategic Outlook
GLOBENEWSWIRE
17 Jan 2023
Share Share
Aeterna discontinues vaccine development; Idera rebrands as Aceragen

Aeterna discontinues vaccine development; Idera rebrands as Aceragen
Paul Schloesser ENDPTS
17 Jan 2023
Share Share
Idera Pharma Reports 3Q 2022 Financial Results and Provides Corporate Update

Idera Pharma Reports 3Q 2022 Financial Results and Provides Corporate Update
GLOBENEWSWIRE
14 Nov 2022
Share Share
Idera buys rare-disease-focused Aceragen in all-stock deal

Idera buys rare-disease-focused Aceragen in all-stock deal
James Waldron FIERCEBIOTECH
30 Sep 2022
Share Share
Idera Pharmaceuticals Acquires Aceragen

Idera Pharmaceuticals Acquires Aceragen
GLOBENEWSWIRE
28 Sep 2022
Share Share
Idera Stops Enrollment in Phase 2 Melanoma Trial Following Positive Early Data

Idera Stops Enrollment in Phase 2 Melanoma Trial Following Positive Early Data
TRIALSITENEWS
19 May 2022
Share Share
Idera Shares Positive Results from Investigator-Sponsored Trial in Melanoma

Idera Shares Positive Results from Investigator-Sponsored Trial in Melanoma
GLOBENEWSWIRE
17 May 2022
Share Share
Idera Pharma Reports First Quarter 2022 Financial Results

Idera Pharma Reports First Quarter 2022 Financial Results
GLOBENEWSWIRE
05 May 2022
Share Share
Idera Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

Idera Pharma Reports Fourth Quarter and Full Year 2021 Financial Results
GLOBENEWSWIRE
31 Mar 2022
Share Share
Idera`s only asset flounders as biotech, AbbVie end enrollment

Idera`s only asset flounders as biotech, AbbVie end enrollment
K. LaHucik FIERCEBIOTECH
16 Dec 2021
Share Share